{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:06:49Z","timestamp":1790651209470,"version":"4.1.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s11030-022-10550-1","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T07:03:27Z","timestamp":1667545407000},"page":"2169-2184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["In silico identification of potential inhibitors of vital monkeypox virus proteins from FDA approved drugs"],"prefix":"10.1007","volume":"27","author":[{"given":"Ajaya Kumar","family":"Sahoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya Dharshini","family":"Augusthian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishwarya","family":"Muralitharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. P.","family":"Vivek-Ananth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishan","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetha","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6796-9604","authenticated-orcid":false,"given":"Areejit","family":"Samal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,4]]},"reference":[{"key":"10550_CR1","unstructured":"WHO (2022) WHO Director-General declares the ongoing monkeypox outbreak a Public Health Emergency of International Concern. https:\/\/www.who.int\/europe\/news\/item\/23-07-2022-who-director-general-declares-the-ongoing-monkeypox-outbreak-a-public-health-event-of-international-concern. Accessed 4 Aug 2022"},{"key":"10550_CR2","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1086\/498115","volume":"41","author":"GD Huhn","year":"2005","unstructured":"Huhn GD, Bauer AM, Yorita K et al (2005) Clinical characteristics of human monkeypox, and risk factors for severe disease. Clin Infect Dis 41:1742\u20131751. https:\/\/doi.org\/10.1086\/498115","journal-title":"Clin Infect Dis"},{"key":"10550_CR3","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S1473-3099(22)00228-6","volume":"22","author":"H Adler","year":"2022","unstructured":"Adler H, Gould S, Hine P et al (2022) Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis 22:1153\u20132116. https:\/\/doi.org\/10.1016\/S1473-3099(22)00228-6","journal-title":"Lancet Infect Dis"},{"key":"10550_CR4","first-page":"593","volume":"46","author":"ID Ladnyj","year":"1972","unstructured":"Ladnyj ID, Ziegler P, Kima E (1972) A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. Bull World health Organ 46:593\u2013597","journal-title":"Bull World health Organ"},{"key":"10550_CR5","first-page":"425","volume":"65","author":"Z Jezek","year":"1987","unstructured":"Jezek Z, Khodakevich LN, Wicketti JF (1987) Smallpox and its post-eradication surveillance. Bull World Health Organ 65:425\u2013434","journal-title":"Bull World Health Organ"},{"key":"10550_CR6","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1099\/vir.0.81215-0","volume":"86","author":"AM Likos","year":"2005","unstructured":"Likos AM, Sammons SA, Olson VA et al (2005) A tale of two clades: monkeypox viruses. J Gen Virol 86:2661\u20132672. https:\/\/doi.org\/10.1099\/vir.0.81215-0","journal-title":"J Gen Virol"},{"key":"10550_CR7","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.3390\/v7042168","volume":"7","author":"Y Nakazawa","year":"2015","unstructured":"Nakazawa Y, Mauldin M, Emerson G et al (2015) A phylogeographic investigation of African Monkeypox. Viruses 7:2168\u20132184. https:\/\/doi.org\/10.3390\/v7042168","journal-title":"Viruses"},{"key":"10550_CR8","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/S1473-3099(19)30294-4","volume":"19","author":"A Yinka-Ogunleye","year":"2019","unstructured":"Yinka-Ogunleye A, Aruna O, Dalhat M et al (2019) Outbreak of human monkeypox in Nigeria in 2017\u201318: a clinical and epidemiological report. Lancet Infect Dis 19:872\u2013879. https:\/\/doi.org\/10.1016\/S1473-3099(19)30294-4","journal-title":"Lancet Infect Dis"},{"key":"10550_CR9","doi-asserted-by":"publisher","first-page":"e554","DOI":"10.1016\/S2666-5247(22)00153-7","volume":"3","author":"A Otu","year":"2022","unstructured":"Otu A, Ebenso B, Walley J et al (2022) Global human monkeypox outbreak: atypical presentation demanding urgent public health action. Lancet Microbe 3:e554\u2013e555. https:\/\/doi.org\/10.1016\/S2666-5247(22)00153-7","journal-title":"Lancet Microbe"},{"key":"10550_CR10","unstructured":"WHO (2022) Multi-country monkeypox outbreak: situation update. https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2022-DON396. Accessed 1 Jul 2022"},{"key":"10550_CR11","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/nm1201-1271","volume":"7","author":"HC Lane","year":"2001","unstructured":"Lane HC, Montagne JL, Fauci AS (2001) Bioterrorism: a clear and present danger. Nat med 7:1271\u20131273. https:\/\/doi.org\/10.1038\/nm1201-1271","journal-title":"Nat med"},{"key":"10550_CR12","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1001\/jama.281.22.2127","volume":"281","author":"DA Henderson","year":"1999","unstructured":"Henderson DA, Inglesby TV, Bartlett JG et al (1999) Smallpox as a biological weapon: medical and public health management. JAMA 281:2127\u20132137. https:\/\/doi.org\/10.1001\/jama.281.22.2127","journal-title":"JAMA"},{"key":"10550_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010141","volume":"16","author":"EM Bunge","year":"2022","unstructured":"Bunge EM, Hoet B, Chen L et al (2022) The changing epidemiology of human monkeypox\u2014a potential threat? A systematic review. PLOS Negl Trop Dis 16:e0010141. https:\/\/doi.org\/10.1371\/journal.pntd.0010141","journal-title":"PLOS Negl Trop Dis"},{"key":"10550_CR14","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/cid\/cit703","volume":"58","author":"AM McCollum","year":"2014","unstructured":"McCollum AM, Damon IK (2014) Human monkeypox. Clin Infect Dis 58:260\u2013267. https:\/\/doi.org\/10.1093\/cid\/cit703","journal-title":"Clin Infect Dis"},{"key":"10550_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2217\/17460913.2.1.17","volume":"2","author":"S Parker","year":"2007","unstructured":"Parker S, Nuara A, Buller RML, Schultz DA (2007) Human monkeypox: an emerging zoonotic disease. Future Microbiol 2:17\u201334. https:\/\/doi.org\/10.2217\/17460913.2.1.17","journal-title":"Future Microbiol"},{"key":"10550_CR16","doi-asserted-by":"publisher","first-page":"11178","DOI":"10.1073\/pnas.0403600101","volume":"101","author":"SC Harrison","year":"2004","unstructured":"Harrison SC, Alberts B, Ehrenfeld E et al (2004) Discovery of antivirals against smallpox. Proc Natl Acad Sci USA 101:11178\u201311192. https:\/\/doi.org\/10.1073\/pnas.0403600101","journal-title":"Proc Natl Acad Sci USA"},{"key":"10550_CR17","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.3390\/v6103787","volume":"6","author":"L Liu","year":"2014","unstructured":"Liu L, Cooper T, Howley P, Hayball J (2014) From crescent to mature virion: vaccinia virus assembly and maturation. Viruses 6:3787\u20133808. https:\/\/doi.org\/10.3390\/v6103787","journal-title":"Viruses"},{"key":"10550_CR18","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a010199","volume":"5","author":"B Moss","year":"2013","unstructured":"Moss B (2013) Poxvirus DNA replication. Cold Spring Harb Perspect Biol 5:a010199. https:\/\/doi.org\/10.1101\/cshperspect.a010199","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10550_CR19","volume-title":"A nutshell: structure and assembly of the vaccinia virion","author":"RC Condit","year":"2006","unstructured":"Condit RC, Moussatche N, Traktman P (2006) A nutshell: structure and assembly of the vaccinia virion. Academic Press, London"},{"key":"10550_CR20","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1074\/mcp.M117.067116","volume":"16","author":"ED Reyes","year":"2017","unstructured":"Reyes ED, Kulej K, Pancholi NJ et al (2017) Identifying host factors associated with DNA replicated during virus infection. Mol Cell Proteom 16:2079\u20132097. https:\/\/doi.org\/10.1074\/mcp.M117.067116","journal-title":"Mol Cell Proteom"},{"key":"10550_CR21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.26531","volume":"14","author":"J Kaler","year":"2022","unstructured":"Kaler J, Hussain A, Flores G et al (2022) Monkeypox: a comprehensive review of transmission, pathogenesis, and manifestation. Cureus 14:e26531. https:\/\/doi.org\/10.7759\/cureus.26531","journal-title":"Cureus"},{"key":"10550_CR22","doi-asserted-by":"publisher","first-page":"7866","DOI":"10.3390\/ijms23147866","volume":"23","author":"D Kmiec","year":"2022","unstructured":"Kmiec D, Kirchhoff F (2022) Monkeypox: a new threat? Int J Mol Sci 23:7866. https:\/\/doi.org\/10.3390\/ijms23147866","journal-title":"Int J Mol Sci"},{"key":"10550_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S1473-3099(03)00856-9","volume":"4","author":"DB Di Giulio","year":"2004","unstructured":"Di Giulio DB, Eckburg PB (2004) Human monkeypox: an emerging zoonosis. Lancet Infect Dis 4:15\u201325. https:\/\/doi.org\/10.1016\/S1473-3099(03)00856-9","journal-title":"Lancet Infect Dis"},{"key":"10550_CR24","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1021\/pr070432+","volume":"7","author":"NP Manes","year":"2008","unstructured":"Manes NP, Estep RD, Mottaz HM et al (2008) Comparative proteomics of human monkeypox and vaccinia intracellular mature and extracellular enveloped virions. J Proteome Res 7:960\u2013968. https:\/\/doi.org\/10.1021\/pr070432+","journal-title":"J Proteome Res"},{"key":"10550_CR25","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1128\/MMBR.00026-09","volume":"73","author":"VV Kim","year":"2009","unstructured":"Kim VV, Leiliang Z et al (2009) Poxvirus proteomics and virus-host protein interactions. Microbiol Mol Biol Rev 73:730\u2013749. https:\/\/doi.org\/10.1128\/MMBR.00026-09","journal-title":"Microbiol Mol Biol Rev"},{"key":"10550_CR26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.tim.2011.12.001","volume":"20","author":"MG Reynolds","year":"2012","unstructured":"Reynolds MG, Damon IK (2012) Outbreaks of human monkeypox after cessation of smallpox vaccination. Trends Microbiol 20:80\u201387. https:\/\/doi.org\/10.1016\/j.tim.2011.12.001","journal-title":"Trends Microbiol"},{"key":"10550_CR27","doi-asserted-by":"publisher","first-page":"638","DOI":"10.2471\/BLT.19.242347","volume":"98","author":"R Grant","year":"2020","unstructured":"Grant R, Nguyen L-BL, Breban R (2020) Modelling human-to-human transmission of monkeypox. Bull World health Organ 98:638\u2013640. https:\/\/doi.org\/10.2471\/BLT.19.242347","journal-title":"Bull World health Organ"},{"key":"10550_CR28","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/ije\/17.3.643","volume":"17","author":"PEM Fine","year":"1988","unstructured":"Fine PEM, Jezek Z, Grab B, Dixon H (1988) The transmission potential of monkeypox virus in human populations. Int J Epedemiol 17:643\u2013650. https:\/\/doi.org\/10.1093\/ije\/17.3.643","journal-title":"Int J Epedemiol"},{"key":"10550_CR29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3121\/cmr.1.2.87","volume":"1","author":"EA Belongia","year":"2003","unstructured":"Belongia EA, Naleway AL (2003) Smallpox vaccine: the good, the bad, and the ugly. Clin Med Res 1:87\u201392. https:\/\/doi.org\/10.3121\/cmr.1.2.87","journal-title":"Clin Med Res"},{"key":"10550_CR30","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40265-022-01742-y","volume":"82","author":"JG Rizk","year":"2022","unstructured":"Rizk JG, Lippi G, Henry BM et al (2022) Prevention and treatment of monkeypox. Drugs 82:957\u2013963. https:\/\/doi.org\/10.1007\/s40265-022-01742-y","journal-title":"Drugs"},{"key":"10550_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jama.2022.10802","volume":"328","author":"J Guarner","year":"2022","unstructured":"Guarner J, del Rio C, Malani PN (2022) Monkeypox in 2022\u2014what clinicians need to know. JAMA 328:139\u2013140. https:\/\/doi.org\/10.1001\/jama.2022.10802","journal-title":"JAMA"},{"key":"10550_CR32","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1056\/NEJMp2210125","volume":"387","author":"A Sherwat","year":"2022","unstructured":"Sherwat A, Brooks JT, Birnkrant D, Kim P (2022) Tecovirimat and the treatment of monkeypox\u2014past, present, and future considerations. N Engl J Med 387:579\u2013581. https:\/\/doi.org\/10.1056\/NEJMp2210125","journal-title":"N Engl J Med"},{"key":"10550_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA et al (2019) Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 18:41\u201358. https:\/\/doi.org\/10.1038\/nrd.2018.168","journal-title":"Nat Rev Drug Discov"},{"key":"10550_CR34","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.therap.2020.02.007","volume":"75","author":"D Scherman","year":"2020","unstructured":"Scherman D, Fetro C (2020) Drug repositioning for rare diseases: knowledge-based success stories. Therapies 75:161\u2013167. https:\/\/doi.org\/10.1016\/j.therap.2020.02.007","journal-title":"Therapies"},{"key":"10550_CR35","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE et al (2020) Remdesivir for the treatment of covid-19\u2014final report. N Engl J Med 383:1813\u20131826. https:\/\/doi.org\/10.1056\/NEJMoa2007764","journal-title":"N Engl J Med"},{"key":"10550_CR36","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1056\/NEJMp2032369","volume":"383","author":"D Rubin","year":"2020","unstructured":"Rubin D, Chan-Tack K, Farley J, Sherwat A (2020) FDA approval of remdesivir\u2014a step in the right direction. N Engl J Med 383:2598\u20132600. https:\/\/doi.org\/10.1056\/NEJMp2032369","journal-title":"N Engl J Med"},{"key":"10550_CR37","doi-asserted-by":"publisher","first-page":"e00162","DOI":"10.1128\/CMR.00162-20","volume":"34","author":"JJ Malin","year":"2020","unstructured":"Malin JJ, Su\u00e1rez I, Priesner V et al (2020) Remdesivir against COVID-19 and other viral diseases. Clin Microbiol Rev 34:e00162-e220. https:\/\/doi.org\/10.1128\/CMR.00162-20","journal-title":"Clin Microbiol Rev"},{"key":"10550_CR38","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3390\/v11040326","volume":"11","author":"EP Tchesnokov","year":"2019","unstructured":"Tchesnokov EP, Feng JY, Porter DP, G\u00f6tte M (2019) Mechanism of inhibition of ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses 11:326. https:\/\/doi.org\/10.3390\/v11040326","journal-title":"Viruses"},{"key":"10550_CR39","doi-asserted-by":"publisher","first-page":"16900","DOI":"10.1073\/pnas.0804525105","volume":"105","author":"C Caillat","year":"2008","unstructured":"Caillat C, Topalis D, Agrofoglio LA et al (2008) Crystal structure of poxvirus thymidylate kinase: an unexpected dimerization has implications for antiviral therapy. Proc Natl Acad Sci USA 105:16900\u201316905. https:\/\/doi.org\/10.1073\/pnas.0804525105","journal-title":"Proc Natl Acad Sci USA"},{"key":"10550_CR40","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1080\/07391102.2013.830578","volume":"32","author":"AP Guimar\u00e3es","year":"2014","unstructured":"Guimar\u00e3es AP, Ramalho TC, Fran\u00e7a TCC (2014) Preventing the return of smallpox: molecular modeling studies on thymidylate kinase from Variola virus. J Biomol Struct Dyn 32:1601\u20131612. https:\/\/doi.org\/10.1080\/07391102.2013.830578","journal-title":"J Biomol Struct Dyn"},{"key":"10550_CR41","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejmech.2014.09.099","volume":"91","author":"AP Guimar\u00e3es","year":"2015","unstructured":"Guimar\u00e3es AP, de Souza FR, Oliveira AA et al (2015) Design of inhibitors of thymidylate kinase from Variola virus as new selective drugs against smallpox. Eur J Med Chem 91:72\u201390. https:\/\/doi.org\/10.1016\/j.ejmech.2014.09.099","journal-title":"Eur J Med Chem"},{"key":"10550_CR42","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1021\/acschembio.2c00049","volume":"17","author":"M Bednarczyk","year":"2022","unstructured":"Bednarczyk M, Peters JK, Kasprzyk R et al (2022) Fluorescence-based activity screening assay reveals small molecule inhibitors of vaccinia virus mRNA decapping enzyme D9. ACS Chem Biol 17:1460\u20131471. https:\/\/doi.org\/10.1021\/acschembio.2c00049","journal-title":"ACS Chem Biol"},{"key":"10550_CR43","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.2174\/0929867311320100006","volume":"20","author":"Q Cui","year":"2013","unstructured":"Cui Q, Shin W, Luo Y et al (2013) Thymidylate kinase: an old topic brings new perspectives. Curr Med Chem 20:1286\u20131305. https:\/\/doi.org\/10.2174\/0929867311320100006","journal-title":"Curr Med Chem"},{"key":"10550_CR44","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3390\/ph15091129","volume":"15","author":"HN Altayb","year":"2022","unstructured":"Altayb HN (2022) Fludarabine, a potential DNA-dependent RNA polymerase inhibitor, as a prospective drug against monkeypox virus: a computational approach. Pharmaceuticals 15:1129. https:\/\/doi.org\/10.3390\/ph15091129","journal-title":"Pharmaceuticals"},{"key":"10550_CR45","doi-asserted-by":"publisher","first-page":"5277","DOI":"10.3390\/molecules27165277","volume":"27","author":"HY Lam","year":"2022","unstructured":"Lam HY, Guan JS, Mu Y (2022) In silico repurposed drugs against monkeypox virus. Molecules 27:5277. https:\/\/doi.org\/10.3390\/molecules27165277","journal-title":"Molecules"},{"key":"10550_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2022.09.002","author":"JM Abduljalil","year":"2022","unstructured":"Abduljalil JM, Elfiky AA (2022) Repurposing antiviral drugs against the human monkeypox virus DNA-dependent RNA polymerase; in silico perspective. J Infect. https:\/\/doi.org\/10.1016\/j.jinf.2022.09.002","journal-title":"J Infect"},{"key":"10550_CR47","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1016\/j.jinf.2022.07.001","volume":"85","author":"D Li","year":"2022","unstructured":"Li D, Liu Y, Li K, Zhang L (2022) Targeting F13 from monkeypox virus and variola virus by tecovirimat: Molecular simulation analysis. J Infect 85:e99\u2013e101. https:\/\/doi.org\/10.1016\/j.jinf.2022.07.001","journal-title":"J Infect"},{"key":"10550_CR48","doi-asserted-by":"publisher","first-page":"6254","DOI":"10.1111\/j.1742-4658.2005.05006.x","volume":"272","author":"D Topalis","year":"2005","unstructured":"Topalis D, Collinet B, Gasse C et al (2005) Substrate specificity of vaccinia virus thymidylate kinase. FEBS J 272:6254\u20136265. https:\/\/doi.org\/10.1111\/j.1742-4658.2005.05006.x","journal-title":"FEBS J"},{"key":"10550_CR49","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.str.2022.02.012","volume":"30","author":"JK Peters","year":"2022","unstructured":"Peters JK, Tibble RW, Warminski M et al (2022) Structure of the poxvirus decapping enzyme D9 reveals its mechanism of cap recognition and catalysis. Structure 30:721-732.e4. https:\/\/doi.org\/10.1016\/j.str.2022.02.012","journal-title":"Structure"},{"key":"10550_CR50","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1124\/pr.112.007336","volume":"66","author":"G Sliwoski","year":"2014","unstructured":"Sliwoski G, Kothiwale S, Meiler J, Lowe EW (2014) Computational methods in drug discovery. Pharmacol Rev 66:334\u2013395. https:\/\/doi.org\/10.1124\/pr.112.007336","journal-title":"Pharmacol Rev"},{"key":"10550_CR51","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3:673\u2013683. https:\/\/doi.org\/10.1038\/nrd1468","journal-title":"Nat Rev Drug Discov"},{"key":"10550_CR52","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/bib\/bbaa421","volume":"22","author":"A Rajput","year":"2021","unstructured":"Rajput A, Kumar A, Megha K et al (2021) DrugRepV: a compendium of repurposed drugs and chemicals targeting epidemic and pandemic viruses. Brief Bioinform 22:1076\u20131084. https:\/\/doi.org\/10.1093\/bib\/bbaa421","journal-title":"Brief Bioinform"},{"key":"10550_CR53","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.tim.2018.04.004","volume":"26","author":"B Mercorelli","year":"2018","unstructured":"Mercorelli B, Pal\u00f9 G, Loregian A (2018) Drug repurposing for viral infectious diseases: how far are we? Trends Microbiol 26:865\u2013876. https:\/\/doi.org\/10.1016\/j.tim.2018.04.004","journal-title":"Trends Microbiol"},{"key":"10550_CR54","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ijantimicag.2016.07.004","volume":"48","author":"P Colson","year":"2016","unstructured":"Colson P, Raoult D (2016) Fighting viruses with antibiotics: an overlooked path. Int J Antimicrob Agents 48:349\u2013352. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.07.004","journal-title":"Int J Antimicrob Agents"},{"key":"10550_CR55","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.celrep.2014.12.054","volume":"10","author":"JRPM Strating","year":"2015","unstructured":"Strating JRPM, van der Linden L, Albulescu L et al (2015) Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein. Cell Rep 10:600\u2013615. https:\/\/doi.org\/10.1016\/j.celrep.2014.12.054","journal-title":"Cell Rep"},{"key":"10550_CR56","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2017","unstructured":"Wishart DS, Feunang YD, Guo AC et al (2017) DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 46:D1074\u2013D1082. https:\/\/doi.org\/10.1093\/nar\/gkx1037","journal-title":"Nucleic Acids Res"},{"key":"10550_CR57","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","volume":"83","author":"DJ Newman","year":"2020","unstructured":"Newman DJ, Cragg GM (2020) Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019. J Nat Prod 83:770\u2013803. https:\/\/doi.org\/10.1021\/acs.jnatprod.9b01285","journal-title":"J Nat Prod"},{"key":"10550_CR58","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/448645a","volume":"448","author":"CR Chong","year":"2007","unstructured":"Chong CR, Sullivan DJ (2007) New uses for old drugs. Nature 448:645\u2013646. https:\/\/doi.org\/10.1038\/448645a","journal-title":"Nature"},{"key":"10550_CR59","doi-asserted-by":"publisher","first-page":"D1080","DOI":"10.1093\/nar\/gkv1192","volume":"44","author":"VB Siramshetty","year":"2016","unstructured":"Siramshetty VB, Nickel J, Omieczynski C et al (2016) WITHDRAWN\u2013a resource for withdrawn and discontinued drugs. Nucleic Acids Res 44:D1080\u2013D1086. https:\/\/doi.org\/10.1093\/nar\/gkv1192","journal-title":"Nucleic Acids Res"},{"key":"10550_CR60","doi-asserted-by":"publisher","first-page":"W296","DOI":"10.1093\/nar\/gky427","volume":"46","author":"A Waterhouse","year":"2018","unstructured":"Waterhouse A, Bertoni M, Bienert S et al (2018) SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res 46:W296\u2013W303. https:\/\/doi.org\/10.1093\/nar\/gky427","journal-title":"Nucleic Acids Res"},{"key":"10550_CR61","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1107\/S0907444909042073","volume":"66","author":"VB Chen","year":"2010","unstructured":"Chen VB, Arendall WB 3rd, Headd JJ et al (2010) MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr 66:12\u201321. https:\/\/doi.org\/10.1107\/S0907444909042073","journal-title":"Acta Crystallogr"},{"key":"10550_CR62","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1","author":"MJ Abraham","year":"2015","unstructured":"Abraham MJ, Murtola T, Schulz R et al (2015) GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1:19\u201325. https:\/\/doi.org\/10.1016\/j.softx.2015.06.001","journal-title":"SoftwareX"},{"key":"10550_CR63","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1002\/jcc.20090","volume":"25","author":"C Oostenbrink","year":"2004","unstructured":"Oostenbrink C, Villa A, Mark AE, Van Gunsteren WF (2004) A biomolecular force field based on the free enthalpy of hydration and solvation: the GROMOS force-field parameter sets 53A5 and 53A6. J Comput Chem 25:1656\u20131676. https:\/\/doi.org\/10.1002\/jcc.20090","journal-title":"J Comput Chem"},{"key":"10550_CR64","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H","volume":"18","author":"B Hess","year":"1997","unstructured":"Hess B, Bekker H, Berendsen HJ, Fraaije JG (1997) LINCS: a linear constraint solver for molecular simulations. J Comput Chem 18:1463\u20131472. https:\/\/doi.org\/10.1002\/(SICI)1096-987X(199709)18:12%3c1463::AID-JCC4%3e3.0.CO;2-H","journal-title":"J Comput Chem"},{"key":"10550_CR65","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1063\/1.448118","volume":"81","author":"HJ Berendsen","year":"1984","unstructured":"Berendsen HJ, van Postma J, Van Gunsteren WF et al (1984) Molecular dynamics with coupling to an external bath. J Chem Phys 81:3684\u20133690. https:\/\/doi.org\/10.1063\/1.448118","journal-title":"J Chem Phys"},{"key":"10550_CR66","doi-asserted-by":"publisher","first-page":"7182","DOI":"10.1063\/1.328693","volume":"52","author":"M Parrinello","year":"1981","unstructured":"Parrinello M, Rahman A (1981) Polymorphic transitions in single crystals: a new molecular dynamics method. J Appl Phys 52:7182\u20137190. https:\/\/doi.org\/10.1063\/1.328693","journal-title":"J Appl Phys"},{"key":"10550_CR67","doi-asserted-by":"publisher","first-page":"5834","DOI":"10.1021\/acs.jctc.8b00768","volume":"14","author":"M Stroet","year":"2018","unstructured":"Stroet M, Caron B, Visscher KM et al (2018) Automated topology builder version 3.0: prediction of solvation free enthalpies in water and hexane. J Chem Theory Comput 14:5834\u20135845. https:\/\/doi.org\/10.1021\/acs.jctc.8b00768","journal-title":"J Chem Theory Comput"},{"key":"10550_CR68","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455\u2013461. https:\/\/doi.org\/10.1002\/jcc.21334","journal-title":"J Comput Chem"},{"key":"10550_CR69","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris GM, Huey R, Lindstrom W et al (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30:2785\u20132791. https:\/\/doi.org\/10.1002\/jcc.21256","journal-title":"J Comput Chem"},{"key":"10550_CR70","unstructured":"DeLano WL (2002) The PyMOL molecular graphics system"},{"key":"10550_CR71","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/nprot.2016.051","volume":"11","author":"S Forli","year":"2016","unstructured":"Forli S, Huey R, Pique ME et al (2016) Computational protein\u2013ligand docking and virtual drug screening with the AutoDock suite. Nat Protoc 11:905\u2013919. https:\/\/doi.org\/10.1038\/nprot.2016.051","journal-title":"Nat Protoc"},{"key":"10550_CR72","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.12688\/f1000research.17456.1","volume":"7","author":"JPGLM Rodrigues","year":"2018","unstructured":"Rodrigues JPGLM, Teixeira JMC, Trellet M, Bonvin AMJJ (2018) pdb-tools: a swiss army knife for molecular structures. F1000Res 7:1961. https:\/\/doi.org\/10.12688\/f1000research.17456.1","journal-title":"F1000Res"},{"key":"10550_CR73","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.3390\/molecules25173822","volume":"25","author":"RP Vivek-Ananth","year":"2020","unstructured":"Vivek-Ananth RP, Rana A, Rajan N et al (2020) In silico identification of potential natural product inhibitors of human proteases key to SARS-CoV-2 infection. Molecules 25:3822. https:\/\/doi.org\/10.3390\/molecules25173822","journal-title":"Molecules"},{"key":"10550_CR74","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1021\/ci500020m","volume":"54","author":"R Kumari","year":"2014","unstructured":"Kumari R, Kumar R, Lynn A (2014) g_mmpbsa\u2013a GROMACS tool for high-throughput MM-PBSA calculations. J Chem Inf Model 54:1951\u20131962. https:\/\/doi.org\/10.1021\/ci500020m","journal-title":"J Chem Inf Model"},{"key":"10550_CR75","doi-asserted-by":"publisher","first-page":"10037","DOI":"10.1073\/pnas.181342398","volume":"98","author":"NA Baker","year":"2001","unstructured":"Baker NA, Sept D, Joseph S et al (2001) Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci USA 98:10037\u201310041. https:\/\/doi.org\/10.1073\/pnas.181342398","journal-title":"Proc Natl Acad Sci USA"},{"key":"10550_CR76","doi-asserted-by":"publisher","first-page":"6234","DOI":"10.1039\/D1RA06702H","volume":"12","author":"RP Vivek-Ananth","year":"2022","unstructured":"Vivek-Ananth RP, Sahoo AK, Srivastava A, Samal A (2022) Virtual screening of phytochemicals from Indian medicinal plants against the endonuclease domain of SFTS virus L polymerase. RSC Adv 12:6234\u20136247. https:\/\/doi.org\/10.1039\/D1RA06702H","journal-title":"RSC Adv"},{"key":"10550_CR77","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s11030-021-10251-1","volume":"26","author":"RP Vivek-Ananth","year":"2022","unstructured":"Vivek-Ananth RP, Krishnaswamy S, Samal A (2022) Potential phytochemical inhibitors of SARS-CoV-2 helicase Nsp13: a molecular docking and dynamic simulation study. Mol Divers 26:429\u2013442. https:\/\/doi.org\/10.1007\/s11030-021-10251-1","journal-title":"Mol Divers"},{"key":"10550_CR78","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/cbdd.13630","volume":"95","author":"\u00c1 Santiago","year":"2020","unstructured":"Santiago \u00c1, Razo-Hern\u00e1ndez RS, Pastor N (2020) The TATA-binding Protein DNA-binding domain of eukaryotic parasites is a potentially druggable target. Chem Biol Drug Des 95:130\u2013149. https:\/\/doi.org\/10.1111\/cbdd.13630","journal-title":"Chem Biol Drug Des"},{"key":"10550_CR79","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2165\/00003088-200645070-00003","volume":"45","author":"JR King","year":"2006","unstructured":"King JR, Acosta EP (2006) Tipranavir. Clin Pharmacokinet 45:665\u2013682. https:\/\/doi.org\/10.2165\/00003088-200645070-00003","journal-title":"Clin Pharmacokinet"},{"key":"10550_CR80","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1021\/jm9802158","volume":"41","author":"SR Turner","year":"1998","unstructured":"Turner SR, Strohbach JW, Tommasi RA et al (1998) Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem 41:3467\u20133476. https:\/\/doi.org\/10.1021\/jm9802158","journal-title":"J Med Chem"},{"key":"10550_CR81","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1586\/14787210.3.1.9","volume":"3","author":"VR Kandula","year":"2005","unstructured":"Kandula VR, Khanlou H, Farthing C (2005) Tipranavir: a novel second-generation nonpeptidic protease inhibitor. Expert Rev Anti-Infect Ther 3:9\u201321. https:\/\/doi.org\/10.1586\/14787210.3.1.9","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"10550_CR82","doi-asserted-by":"publisher","first-page":"S538","DOI":"10.1093\/cid\/ciz826","volume":"69","author":"T Sato","year":"2019","unstructured":"Sato T, Yamawaki K (2019) Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clin Infect Dis 69:S538\u2013S543. https:\/\/doi.org\/10.1093\/cid\/ciz826","journal-title":"Clin Infect Dis"},{"key":"10550_CR83","unstructured":"WHO (2021) World Health Organization model list of essential medicines: 22nd list"},{"key":"10550_CR84","unstructured":"FDA (2020) FDA approves new antibacterial drug to treat complicated urinary tract infections as part of ongoing efforts to address antimicrobial resistance. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-antibacterial-drug-treat-complicated-urinary-tract-infections-part-ongoing-efforts. Accessed 29 Jun 2022"},{"key":"10550_CR85","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00387","volume":"1","author":"AG Patel","year":"2012","unstructured":"Patel AG, Kaufmann SH (2012) How does doxorubicin work? Elife 1:e00387. https:\/\/doi.org\/10.7554\/eLife.00387","journal-title":"Elife"},{"key":"10550_CR86","doi-asserted-by":"crossref","unstructured":"Arcamone F, Cassinelli G, Franceschi G, et al (1972) Structure and physicochemical properties of adriamycin (doxorubicin). In: International symposium on adriamycin; Springer. International symposium on adriamycin; Springer, pp 9\u201322","DOI":"10.1007\/978-3-642-95227-2_2"},{"key":"10550_CR87","unstructured":"Weiss RB (1992) The anthracyclines: will we ever find a better doxorubicin? In: Seminars in Oncology. Seminars in Oncology, pp 670\u2013686"},{"key":"10550_CR88","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/cid\/ciu221","volume":"59","author":"DA Osterholzer","year":"2014","unstructured":"Osterholzer DA, Goldman M (2014) Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection. Clin Infect Dis 59:265\u2013271. https:\/\/doi.org\/10.1093\/cid\/ciu221","journal-title":"Clin Infect Dis"},{"key":"10550_CR89","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40121-013-0020-8","volume":"2","author":"T Mespl\u00e8de","year":"2013","unstructured":"Mespl\u00e8de T, Wainberg MA (2013) Integrase strand transfer inhibitors in HIV therapy. Infect Dis Ther 2:83\u201393. https:\/\/doi.org\/10.1007\/s40121-013-0020-8","journal-title":"Infect Dis Ther"},{"key":"10550_CR90","unstructured":"WHO (2019) WHO recommends dolutegravir as preferred HIV treatment option in all populations. https:\/\/www.who.int\/news\/item\/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations. Accessed 7 Jul 2022"},{"key":"10550_CR91","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/cpt.1909","volume":"108","author":"U Arshad","year":"2020","unstructured":"Arshad U, Pertinez H, Box H et al (2020) Prioritization of anti-SARS-Cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics. Clin Pharmacol Ther 108:775\u2013790. https:\/\/doi.org\/10.1002\/cpt.1909","journal-title":"Clin Pharmacol Ther"},{"key":"10550_CR92","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1016\/j.jiph.2020.10.015","volume":"13","author":"P Indu","year":"2020","unstructured":"Indu P, Rameshkumar MR, Arunagirinathan N et al (2020) Raltegravir, indinavir, tipranavir, dolutegravir, and etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: a molecular docking and drug repurposing approach. J Infect Public Health 13:1856\u20131861. https:\/\/doi.org\/10.1016\/j.jiph.2020.10.015","journal-title":"J Infect Public Health"},{"key":"10550_CR93","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3390\/microorganisms8040599","volume":"8","author":"M Stefanik","year":"2020","unstructured":"Stefanik M, Valdes JJ, Ezebuo FC et al (2020) FDA-approved drugs efavirenz, tipranavir, and dasabuvir inhibit replication of multiple flaviviruses in vero cells. Microorganisms 8:599. https:\/\/doi.org\/10.3390\/microorganisms8040599","journal-title":"Microorganisms"},{"key":"10550_CR94","doi-asserted-by":"publisher","first-page":"e00685","DOI":"10.1128\/AAC.00685-20","volume":"65","author":"B Delaney","year":"2021","unstructured":"Delaney B, Gemma R, Andrew H et al (2021) Burkholderia pseudomallei clinical isolates are highly susceptible in vitro to cefiderocol, a siderophore cephalosporin. Antimicrob Agents Chemother 65:e00685-e720. https:\/\/doi.org\/10.1128\/AAC.00685-20","journal-title":"Antimicrob Agents Chemother"},{"key":"10550_CR95","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ijantimicag.2018.11.007","volume":"53","author":"JA Karlowsky","year":"2019","unstructured":"Karlowsky JA, Hackel MA, Tsuji M et al (2019) In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015\u20132016: SIDERO-WT-2015. Int J Antimicrob Agents 53:456\u2013466. https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.11.007","journal-title":"Int J Antimicrob Agents"},{"key":"10550_CR96","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2021.1905551","author":"QM Sajid Jamal","year":"2021","unstructured":"Sajid Jamal QM, Alharbi AH, Ahmad V (2021) Identification of doxorubicin as a potential therapeutic against SARS-CoV-2 (COVID-19) protease: a molecular docking and dynamics simulation studies. J Biomol Struct Dyn. https:\/\/doi.org\/10.1080\/07391102.2021.1905551","journal-title":"J Biomol Struct Dyn"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-022-10550-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-022-10550-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-022-10550-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:16:53Z","timestamp":1744157813000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-022-10550-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,4]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10550"],"URL":"https:\/\/doi.org\/10.1007\/s11030-022-10550-1","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,4]]},"assertion":[{"value":"21 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is a purely computational study and ethics approvals are not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All co-authors have read and approved the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}